Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...